Evidence map›Paper›PMID 34497606›Full record

ArticleFrontiers in immunology2021

Siglec-H-Deficient Mice Show Enhanced Type I IFN Responses, but Do Not Develop Autoimmunity After Influenza or LCMV Infections.

Nadine Szumilas, Odilia B J Corneth, Christian H K Lehmann, Heike Schmitt, Svenia Cunz, Jolie G Cullen, Talyn Chu, Anita Marosan, Attila Mócsai, Vladimir Benes and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. The role of DAP12 in immune-related inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Nadine SzumilasDivision of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erlangen, Germany.
Odilia B J CornethDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Christian H K LehmannLaboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
Heike SchmittFirst Department of Medicine, University Hospital Erlangen, Erlangen, Germany.
Svenia CunzDivision of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erlangen, Germany.
Jolie G CullenDivision of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.
Talyn ChuDivision of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.
Anita MarosanDepartment of Immune Modulation, University Hospital Erlangen, Erlangen, Germany.
Attila MócsaiSemmelweis University School of Medicine, Budapest, Hungary.
Vladimir BenesGenomics Core Facility, EMBL Heidelberg, Heidelberg, Germany.
Dietmar ZehnDivision of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.
Diana DudziakLaboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
Rudi W HendriksDepartment of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Lars NitschkeDivision of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erlangen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DETechnical University of Munich · DEUniversitätsklinikum Erlangen · DEErasmus MC · NLSemmelweis University · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Siglec-H is a DAP12-associated receptor on plasmacytoid dendritic cells (pDCs) and microglia. Siglec-H inhibits TLR9-induced IFN-α production by pDCs. Previously, it was found that Siglec-H-deficient mice develop a lupus-like severe autoimmune disease after persistent murine cytomegalovirus (mCMV) infection. This was due to enhanced type I interferon responses, including IFN-α. Here we examined, whether other virus infections can also induce autoimmunity in Siglec-H-deficient mice. To this end we infected Siglec-H-deficient mice with influenza virus or with Lymphocytic Choriomeningitis virus (LCMV) clone 13. With both types of viruses we did not observe induction of autoimmune disease in Siglec-H-deficient mice. This can be explained by the fact that both types of viruses are ssRNA viruses that engage TLR7, rather than TLR9. Also, Influenza causes an acute infection that is rapidly cleared and the chronicity of LCMV clone 13 may not be sufficient and may rather suppress pDC functions. Siglec-H inhibited exclusively TLR-9 driven type I interferon responses, but did not affect type II or type III interferon production by pDCs. Siglec-H-deficient pDCs showed impaired Hck expression, which is a Src-family kinase expressed in myeloid cells, and downmodulation of the chemokine receptor CCR9, that has important functions for pDCs. Accordingly, Siglec-H-deficient pDCs showed impaired migration towards the CCR9 ligand CCL25. Furthermore, autoimmune-related genes such as Klk1 and DNase1l3 are downregulated in Siglec-H-deficient pDCs as well. From these findings we conclude that Siglec-H controls TLR-9-dependent, but not TLR-7 dependent inflammatory responses after virus infections and regulates chemokine responsiveness of pDCs.

Indexed as

AnimalsArenaviridae InfectionsAutoimmune DiseasesAutoimmunityChemotaxis, LeukocyteDendritic CellsInfluenza A Virus, H3N2 SubtypeInterferon Type ILectinsLymphocytic choriomeningitis virusMiceMice, Inbred C57BLMice, KnockoutOrthomyxoviridae InfectionsReceptors, Cell SurfaceToll-Like Receptor 9Interferon Type ILectinsReceptors, Cell SurfaceSiglech protein, mouseTlr9 protein, mouseToll-Like Receptor 9Interferon-alphaplasmacytoid dendritic cellsSiglecSLETLR9

Identifiers

PMID34497606
PMCPMC8419311
OpenAlexW3194962262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.